Ligand (LGND) Breakout! Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout!

LGND 200.29

0.0%

Jan 8 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Andrew H who wrote (13629)	1/23/1998 1:00:00 AM
From: Henry Niman	of 32384

Andy, I think that the Premarin results, as well as the Drolxifene results, will really heat up the SERM race for osteoporsis and LGND will be in the thick of the battle. The PFE deal is really for osteoporosis as is AHP's TSE424. AHP will be even more anxious to get moving on TSE424 because Premarin is under fire, Evista goes on sale this month, and now PFE is focused on Droloxifene for osteoporosis (and I suspect that they are also planning on speeding up CP-366,156 dsevelopment - LGND has indicated that CP-366,156 is more efffective than Droloxifene). Moreover, the Droloxifene result may focus development of a rexinoid/Evista combo for breast cancer, which is part of the recent LLY deal.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next